Researchers concluded that there has been significant expansion of coverage for ctDNA assays over the past four years, but policies remain very heterogeneous and often limited.
Investigators plan to tap into large genomic and other datasets with an in silico patient to simulate drug responses, uncover treatment targets, and assess therapies.
A Myriad Genetics-funded team found that an 86-SNV polygenic score could modify breast cancer risk in women with pathogenic mutations in cancer risk genes.
The company recently presented results from its Aurora assay for multi-cancer screening and plans to launch a $100 test for the US and Chinese markets.
In a separate study, researchers studying the use of Oncotype DX in African-American men found it to be predictive of disease outcomes regardless of race.
The approval is supported by a randomized trial showing that pembrolizumab nearly doubled progression-free survival compared to the standard chemotherapy regimen.
